Edition:
India

Teijin Ltd (3401.T)

3401.T on Tokyo Stock Exchange

2,517JPY
11:17am IST
Change (% chg)

¥-24 (-0.94%)
Prev Close
¥2,541
Open
¥2,562
Day's High
¥2,566
Day's Low
¥2,514
Volume
767,000
Avg. Vol
1,529,238
52-wk High
¥2,603
52-wk Low
¥2,018

Select another date:

Fri, Dec 1 2017

BRIEF-Teijin To Invest 35 Billion Yen To Build Carbon Fiber Plant In U.S. -Nikkei

* TEIJIN TO INVEST 35 BILLION YEN TO BUILD CARBON FIBER PLANT IN U.S. -NIKKEI Source text: (http://s.nikkei.com/2Al5U6z) Further company coverage:

BRIEF-Teijin to merge with fiber unit

* Says it will merge with a Tokyo-based fiber consolidated subsidiary

BRIEF-R&I affirms Teijin's rating at "A-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I

BRIEF-Teijin lowers conversion price for 2018 due euro-yen denominated convertible bonds and 2021 due euro-yen denominated convertible bonds

* Says it lowered the conversion price for 2018 due euro-yen denominated convertible bonds to 2,026 yen per share, from 2,035.7 yen per share, after Oct. 1

BRIEF-Merz, Teijin announce partnership to bring Xeomin to Japan

* Merz and Teijin announce partnership to bring Xeomin (Incobotulinumtoxina) to Japan

BRIEF- Teijin to transfer rights and obligations to unit TEIJIN FRONTIER

* Says it will transfer rights and obligations, including inventories, investment securities and capital invested into group company, to wholly owned unit TEIJIN FRONTIER CO., LTD.

BRIEF- JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin

* Says it entered into co-development and license agreement with Teijin Ltd, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18

Select another date: